ArticleRadiology. Imaging cancer2026
US Molecular Imaging of Glypican-3 Expression in Hepatocellular Carcinoma Using Targeted Biosynthetic Gas Vesicles.
Article in Radiology. Imaging cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- GV21 enables ultrasound molecular imaging of tumor cell-associated VEGFR2 for early therapy assessment.Materials today. Bio · 2026Article
- A Look Behind the Paper: Glypican-3-targeted US Molecular Imaging of Hepatocellular Carcinoma.Radiology. Imaging cancer · 2026Article
- Molecular Imaging of Hepatocellular Carcinoma with Third-Generation US Contrast Agents: Toward Clinical Translation.Radiology. Imaging cancer · 2026Article
- Preoperative Prediction of Glypican-3 Expression in Hepatocellular Carcinoma Using Sonazoid Contrast-Enhanced Ultrasound Radiomics.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose To develop L5 peptide-modified gas vesicles (L5-GVs) for US molecular imaging (USMI) of glypican-3 (GPC3) expression in hepatocellular carcinoma (HCC). Materials and Methods This study was conducted from October 2022 to December 2024. L5-GVs were synthesized by conjugating L5 peptides to gas vesicles derived from
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.